Abbott Laboratories is facing a proposed class action lawsuit alleging that its PediaSure Grow & Gain nutrition drinks were marketed in a way that misled parents and caregivers into believing the products were clinically proven to make children grow taller. On June 4, 2026, U.S. District Judge Paul Engelmayer of the Manhattan federal court ruled that Abbott must face the suit, rejecting the company’s bid to dismiss it and sending the case into discovery. The core claim is straightforward: the packaging and advertising, plaintiffs say, framed “grow” as height gain when the science behind the product does not support that promise for ordinary, healthy children.
The lawsuit was brought by named plaintiff Joanne Noriega, a grandmother who bought PediaSure to help her grandson grow. According to her complaint, after roughly a year of daily PediaSure use, the boy remained short — but became overweight. Her experience, her attorney James Denlea argues, is exactly what happens when a calorie-dense supplement is sold to families as a height solution. Abbott denies the allegations, calling its labeling “appropriate” and describing PediaSure as “a scientifically designed complete and balanced nutrition solution for children to help support growth and development.” No settlement exists in the case; as of June 2026 it is in the discovery phase.
Table of Contents
- What Does the PediaSure Class Action Actually Claim Was Misleading?
- The “Clinically Proven” Language and the Fine Print Problem
- Abbott’s Earlier Courtroom Win: The Sugar-Content Case
- What Families Who Bought PediaSure Should Know Right Now
- Why Class Certification Is the Next Big Hurdle
- Other Abbott Labeling Litigation to Watch
- The Judge and Court Handling the Case
- Frequently Asked Questions
What Does the PediaSure Class Action Actually Claim Was Misleading?
The complaint centers on how the Grow & Gain label communicates its promise. Judge Engelmayer found that the packaging’s cartoon giraffe, paired with ruler-like markings climbing up to the giraffe’s head, could lead a reasonable consumer to read “grow” as height gain and “gain” as weight gain. That visual shorthand matters legally.
Consumer protection law in most states asks not what a company technically said, but what a reasonable shopper would take away from the whole presentation — images, words, and context together. The judge also pointed beyond the bottle. He cited an Abbott television advertisement showing a boy playing basketball with taller boys, remarking that he has “a lot to look up to.” In the court’s view, that ad reinforced the height message the label already suggested. Compare this to how courts treat vague puffery like “helps kids thrive,” which is usually too general to be actionable: here, the combination of a growth chart motif, a tall animal, and a short-kid-among-tall-kids commercial gave the plaintiffs a concrete, measurable claim — that Abbott implied height gains it could not clinically substantiate for the general population of children.
The “Clinically Proven” Language and the Fine Print Problem
A key battleground in the case is what “clinically proven” actually referred to. Abbott’s clinical studies on PediaSure involved children “at risk” of malnutrition — a specific, medically defined population. The plaintiffs argue that most parents buying Grow & Gain at the grocery store are feeding it to picky eaters or kids of ordinary stature, not clinically malnourished children, and that the disclaimers limiting the studied population were easy to miss. Judge Engelmayer declined to strike testimony from a Columbia Business School professor who opined that Abbott’s marketing framed “grow” as height and that consumers would not notice the disclaimers about the “at risk” study population.
That expert testimony surviving the motion stage is significant: it means the plaintiffs enter discovery with a marketing-perception opinion already in the record. The limitation worth understanding here is that a ruling denying dismissal is not a finding of liability. The court decided only that a reasonable consumer *could* be misled — a plausibility threshold. Abbott says it is confident the evidence will show the allegations are unfounded, and discovery could still produce facts that defeat class certification or the claims themselves.
Abbott’s Earlier Courtroom Win: The Sugar-Content Case
Abbott has been down this road before — and won. In a separate, earlier California class action, plaintiffs alleged that PediaSure Grow & Gain and Sidekicks labels falsely conveyed that the products were healthy and balanced despite excessive added sugar. The numbers were striking: two bottles a day, as recommended, delivered 46 grams of added sugar — roughly 11 teaspoons — which is approximately double to quadruple the American Heart Association’s daily upper limit for added sugar, depending on the child’s age. That case went the distance.
In February 2025, after about six years of litigation, a California jury returned a complete defense verdict for Abbott, finding the labels were not misleading. The lawsuit had sought roughly $250 million. The verdict is a concrete reminder that surviving a motion to dismiss — as the current height-claims case just did — is a long way from winning at trial. Juries have shown they can look at PediaSure’s labeling and side with Abbott.
What Families Who Bought PediaSure Should Know Right Now
For consumers, the practical picture is simple: there is nothing to file yet in the height-claims case. No settlement exists, no claims process is open, and the litigation is in discovery as of June 2026. If the class is eventually certified and the case settles or plaintiffs prevail, purchasers of Grow & Gain during the relevant period would typically be notified and given a window to submit claims, usually with proof of purchase or an attestation. The tradeoff families face in the meantime is a nutritional one, not just a legal one.
PediaSure is genuinely useful for children with medically identified nutrition deficits — that is the population it was studied in. For a typical child of shorter stature, the calorie load can cut the other way, as Noriega’s complaint alleges happened to her grandson: no height gain, but unwanted weight gain. Parents concerned about a child’s growth trajectory get more reliable answers from a pediatrician and a growth-chart evaluation than from a supplement aisle. Saving receipts and purchase records is a low-cost hedge in case a claims process opens later.
Why Class Certification Is the Next Big Hurdle
The case now moves into discovery, where both sides will exchange documents, depose witnesses, and build expert records — but the pivotal fight ahead is class certification. Plaintiffs must show that the alleged deception affected purchasers in a common enough way to be tried collectively, and that damages can be calculated on a classwide basis. Abbott will likely argue that people bought PediaSure for many different reasons — weight gain for underweight kids, meal replacement for picky eaters, doctor recommendations — undermining the claim that a height message drove purchases across the board.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
A warning for anyone tracking this case: timelines in consumer class actions are long, and outcomes are uncertain. The California sugar case took roughly six years to reach a jury and ended in a total loss for the plaintiffs. Denial of a motion to dismiss generates headlines, but historically many such cases end in decertification, summary judgment, or defense verdicts. Consumers should be skeptical of any third party claiming money is currently available from a “PediaSure settlement” — none exists in this case.
Other Abbott Labeling Litigation to Watch
The height-claims case is not the only front-label dispute Abbott faces. A separate class action, covered by AboutLawsuits.com, alleges that Abbott misrepresented the nutritional value of both PediaSure and Similac products on their front labels, including claims of pediatrician support. That suit reflects a broader litigation trend targeting the gap between prominent front-of-package health claims and the actual nutritional content disclosed in smaller print — the same asymmetry at the heart of the Grow & Gain complaint.
The Judge and Court Handling the Case
The height-claims case is proceeding in the U.S. District Court for the Southern District of New York before Judge Paul Engelmayer, a jurist with substantial experience in complex consumer and commercial litigation.
His June 4, 2026 ruling did two consequential things at once: it held that the giraffe-and-ruler imagery plausibly conveyed a height promise, and it preserved the plaintiffs’ consumer-perception expert over Abbott’s objection. Both rulings shape the evidentiary landscape the parties now carry into discovery, where Abbott’s internal marketing documents and clinical study files are likely to become central exhibits.
Frequently Asked Questions
Is there a PediaSure settlement I can claim money from?
No. The active height-claims case has no settlement; it entered discovery after the June 4, 2026 ruling. Any third party claiming otherwise should be treated with suspicion.
What exactly does the lawsuit say was misleading?
That the Grow & Gain label — a cartoon giraffe with ruler-like markings — plus TV ads implied the drink was clinically proven to help children grow taller, when studies involved children at risk of malnutrition.
Has Abbott lost a PediaSure lawsuit before?
No — in fact it won. In February 2025, a California jury rejected a roughly $250 million class action over added sugar content, finding the labels were not misleading.
Who filed the current lawsuit?
Named plaintiff Joanne Noriega, represented by attorney James Denlea. She alleges her grandson drank PediaSure daily for about a year, stayed short, and became overweight.
What is Abbott’s response?
Abbott says its labeling is “appropriate,” describes PediaSure as a scientifically designed complete and balanced nutrition product, and says it is confident the evidence will show the allegations are unfounded.
You Might Also Like
- Tesla Quebec Heat Pump Class Action Claims Cold-Weather Failures Could Cost Up to $400 Million
- Social media bellwether trial limits expert testimony on platform liability claims
- New York Legal Action: Chemical Industry Faces PFAS Contamination Liability Claims